Stoke Therapeutics (NASDAQ:STOK) Receives “Buy” Rating from Chardan Capital

Chardan Capital reiterated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $24.00 target price on the stock.

Other research analysts also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday. Finally, HC Wainwright increased their price target on Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $8.33 on Wednesday. The company has a market capitalization of $441.24 million, a PE ratio of -3.97 and a beta of 0.95. The business has a fifty day moving average price of $10.55 and a two-hundred day moving average price of $12.29. Stoke Therapeutics has a 1 year low of $5.21 and a 1 year high of $17.58.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the transaction, the insider now owns 51,277 shares in the company, valued at $618,913.39. This trade represents a 16.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,170 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the transaction, the chief executive officer now owns 68,671 shares of the company’s stock, valued at approximately $877,615.38. This represents a 8.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,849 shares of company stock worth $809,421 in the last quarter. 11.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Barclays PLC raised its holdings in shares of Stoke Therapeutics by 145.3% in the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after acquiring an additional 47,239 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Stoke Therapeutics by 9.7% in the 3rd quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after acquiring an additional 76,661 shares in the last quarter. State Street Corp raised its holdings in shares of Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after acquiring an additional 137,145 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after acquiring an additional 71,647 shares in the last quarter. Finally, RTW Investments LP raised its holdings in shares of Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after acquiring an additional 427,447 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.